I will fully admit that I am embarrassed to have a governor that has pretended to fix our education problems by banning cell phones in schools, but ask yourself, what has Governor Ayotte accomplished, other than this? Her opponent, Cindi Warmington’s record stands in sharp contrast.
The role of the lone partisan outlier on a governing body requires an intricate balance of fierce public resistance and quiet compromise. During her four years as the lone Democrat on New Hampshire’s Executive Council, Cinde Warmington provided a masterclass in this political balancing act. Facing a staunch 4-1 Republican majority, her tenure was defined by an ability to transform her solitary platform into tangible victories for her constituents.
While Warmington frequently made headlines as a vocal opponent of conservative policy, her most enduring achievements were rooted in pragmatism. Her legal acumen allowed her to identify critical pressure points within state contracts, enabling her to secure vital funding for substance abuse treatment and mental health infrastructure across District 2. Furthermore, she effectively crossed the aisle to help green-light a historic $100 million investment in affordable housing, a critical move toward addressing the state's severe supply crisis.
Ultimately, Warmington proved that a supermajority does not dictate absolute power. Her executive council legacy is a powerful reminder that principled, strategic minority leaders can still deliver meaningful progress through gridlock.
Why Kelly Ayotte needs to focus on Cindi Warmington’s record instead of her own.
The political legacy of Kelly Ayotte is inextricably bound to a Faustian bargain with Big Pharma. During her time in the U.S. Senate, Ayotte rake-off approximately $138,650 from the pharmaceutical industry, making her the top NH recipient of drug-money influence during that era. Worse still is the $83,049 traced to opioid manufacturers, distributors, and the Sackler family—producers of OxyContin.
This is not just a compliance issue; it is a profound moral failure. While corporate cash lined Ayotte’s campaign coffers, New Hampshire communities were hollowed out by an unprecedented opioid crisis. Families buried their children while the Sackler’s amassed billions and politicians like Ayotte cashed the checks. Ayotte’s leadership PAC even accepted $3,125 directly from Purdue Pharma’s owners.
This corporate capture dates back to her tenure as New Hampshire’s Attorney General. In 2007, she chose not to join a multi-state lawsuit against Purdue Pharma, a decision that shielded the predatory drugmaker from early accountability. Years later, as a Senator, she continued to accept their financial backing.
Defenders claim these donations merely represent individual support for her broader legislative record, but the optics are indefensible. You cannot claim to fight an epidemic while bankrolled by the cartels who engineered it.
Kelly Ayotte’s reliance on Big Pharma cash exposes a transactional political culture where corporate profit outweighs public health. This track record demands strict public accountability. New Hampshire voters must ask themselves: can a leader who fueled her political rise with opioid industry money ever truly be trusted to put families over corporate special interests?
Kelly Ayotte’s relationship with the healthcare industry goes far deeper than campaign contributions; it is written directly into her legislative voting record. During her tenure in the U.S. Senate, Ayotte repeatedly voted to dismantle the Patient Protection and Affordable Care Act (Obamacare), a move that critics note would have stripped healthcare coverage from approximately 50,000 Granite Staters who relied on the state's Medicaid expansion. Furthermore, her alignment with corporate interests extended to voting against allowing Americans to import cheaper prescription drugs from Canada, directly favoring the profit margins of Big Pharma over affordable patient care.
The Absence of Moral Authority
The reality of Kelly Ayotte’s corporate pharmaceutical ties effectively strips her of the moral authority to lecture anyone on the ethics of the opioid crisis. Weaponizing a brief, nine-month legal assignment that Cinde Warmington was handed by her law firm nearly 25 years ago is a glaring double standard. In 2001, when that assignment occurred, the medical establishment widely viewed OxyContin as a breakthrough for severe pain management because Purdue Pharma actively lied about and concealed its addictive traits. Warmington was a junior attorney executing an assigned task long before the catastrophic dangers of widespread opioid use were fully established or understood by the general public.
There is a vast ethical chasm between a young lawyer handling a client assigned by her firm under false medical premises, and a powerful U.S. Senator choosing to rake in over $80,000 in opioid-linked campaign cash. Ayotte chose to accept those funds—including direct contributions from the Sackler family—years later, at a time when the devastating reality of the opioid epidemic was already tearing New Hampshire families apart.
Ayotte's attempt to rewrite history and position herself as a public health champion ignores the timeline of her own financial choices. A politician who financed her political career with the help of the very corporate entities that engineered and profited from the addiction crisis cannot credibly throw stones at an opponent's decades-old legal resume. This strategy relies on distraction rather than accountability, showing that when it comes to the pharmaceutical industry, Ayotte's standards apply to her rivals, but never to her own campaign ledger.
The campaign finance reports for the 2026 New Hampshire gubernatorial race expose a glaring, undeniable truth: incumbent Republican Kelly Ayotte has completely sold out Granite Staters to bankroll her multi-million-dollar war chest. While paying hollow lip service to working families, Ayotte’s campaign is being systematically propped up by out-of-state corporate predators, multi-millionaire executives, and the very Wall Street interests driving up the cost of living.
Nowhere is this betrayal clearer than Ayotte’s deep financial ties to board members and executives linked to predatory real estate giants like Blackstone and institutional housing investors. At a time when everyday people in New Hampshire are facing a crushing housing crisis, Ayotte is eagerly pocketing cash from the ultra-wealthy Massachusetts private equity elites who treat local neighborhoods like a Monopoly board. Her hypocritical campaign slogan, "Don't MASS Up New Hampshire," is a fraudulent joke; she has no problem "Massing up" her own bank accounts with Boston real estate cash, ensuring that out-of-state billionaires pull the strings in Concord.
The contrast with Democratic challenger Cinde Warmington could not be sharper. Warmington’s campaign is powered by the people, drawing 92% of her individual contributions from local residents within New Hampshire. Warmington is beholden to the voters; Ayotte is beholden to the boardrooms.
By allowing national political machines like the Republican Governors Association to dump a massive $2 million infusion into her race alongside corporate checks, Ayotte has made it clear whose interests she will protect in office. A politician bought by out-of-state real estate conglomerates and corporate monopolies will always prioritize corporate profits over community needs. New Hampshire’s highest office belongs to the people of New Hampshire, and it is time to reject a candidate who has traded her loyalty to Granite Staters for a corporate paycheck.